• In late April 2026, Mirion Technologies reported first‑quarter revenue of US$257.6 million, up from US$202.0 million a year earlier, but posted a modest net loss of US$3.4 million while reaffirming full‑year 2026 revenue growth guidance of approximately 22%–24%, supported by acquisition and foreign exchange tailwinds.
• The quarter also brought a 42% surge in total orders to US$288 million including Paragon and Certrec, a US$1.1 billion backlog, and fresh institutional interest from Vanguard, underscoring Mirion’s deepening exposure to accelerating nuclear power demand and expanding multi‑year project visibility.
• We’ll now examine how this combination of strong order backlog growth and reaffirmed revenue guidance may influence Mirion’s investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 37 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Mirion Technologies Investment Narrative Recap

To own Mirion, you need to believe that growing demand for nuclear and medical radiation solutions will translate into sustained order growth and better earnings over time. The latest results support that narrative via a 42% jump in orders and a US$1.1 billion backlog, even though Mirion slipped to a small net loss and slightly trimmed adjusted EPS guidance. For now, the most important near term catalyst remains execution on this larger backlog, while integration and margin pressure from acquisitions stay the key risk.

The reaffirmed 2026 revenue growth guidance of about 22% to 24%, helped by acquisitions and foreign exchange, is the announcement that most directly ties into this story. It shows management still expects the enlarged backlog and recent deals like Paragon and Certrec to support top line growth, even as earnings guidance edges down due to a one off CEO retention grant. However, investors should also weigh how acquisition led expansion could affect profitability if...

Mirion Technologies' narrative projects $1.3 billion revenue and $138.0 million earnings by 2029.

Uncover how Mirion Technologies' forecasts yield a $28.10 fair value, a 43% upside to its current price.

Exploring Other Perspectives

Four fair value estimates from the Simply Wall St Community span roughly US$16.75 to US$28.10, showing how far apart individual views on Mirion’s potential can be. Against this backdrop, Mirion’s reliance on acquisition driven growth and integration success becomes even more important for you to assess, given its influence on future margins and cash generation.

Explore 4 other fair value estimates on Mirion Technologies - why the stock might be worth 15% less than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Mirion Technologies research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Mirion Technologies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Mirion Technologies' overall financial health at a glance.

Ready For A Different Approach?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.
• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.